****

## The corresponding author responsible for the submission of the manuscript to the *Revista* *Brasileira* *de Cancerologia* should download the file, fill, sign and attach to the original of the manuscript as**.pdf.**

## **Title of the manuscript: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

# \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Author:

Author:

Author:

Author:

Author:

Author:

Author:

Author:

Author:

# Classification of the manuscript:

( ) Original Article: ( ) Quantitative ( ) Qualitative ( ) Mixed ( ) Clinical Trial

( ) Literature review: ( ) Integrative ( ) Systematic

( ) Case Series/Report

( ) Short Report

( ) Opinion Piece

( ) Opinion Piece – invitation

( ) Review

( ) Letter to the Editor

# ( ) First submission

# ( ) Resubmission after rejected. Resubmission will be accepted only two months after the article

#  was rejected. If resubmitted, inform the registry number earlier created by the system.

# Number: \_\_\_\_\_\_\_\_\_\_.

**Has the manuscript been deposited as preprint?**

#  ( ) No

#  ( ) Yes. Name of the public employee \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

#  DOI number \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Institutional Review Board (IRB) approval:**

( ) Waives approval

( ) Number of Approval CAAE (registry of ethical approval by CEP/CONEP) (local IRB and National Ethics Committee) “*Plataforma Brasil*”. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Indicate the contributions of each author checking the fields below:

# Contributions:

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Conception OR design of the study; OR acquisition, analysis, OR interpretation of the research data; ( ) Drafting OR critical review with intellectual contribution; ( ) Final approval of the version for publication.

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Conception OR design of the study; OR acquisition, analysis, OR interpretation of the research data; ( ) Drafting OR critical review with intellectual contribution; ( ) Final approval of the version for publication.

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Conception OR design of the study; OR acquisition, analysis, OR interpretation of the research data; ( ) Drafting OR critical review with intellectual contribution; ( ) Final approval of the version for publication.

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Conception OR design of the study; OR acquisition, analysis, OR interpretation of the research data; ( ) Drafting OR critical review with intellectual contribution; ( ) Final approval of the version for publication.

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Conception OR design of the study; OR acquisition, analysis, OR interpretation of the research data; ( ) Drafting OR critical review with intellectual contribution; ( ) Final approval of the version for publication.

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Conception OR design of the study; OR acquisition, analysis, OR interpretation of the research data; ( ) Drafting OR critical review with intellectual contribution; ( ) Final approval of the version for publication.

# Conflict of interests:

( ) The author(s) has/have no conflict of interests, including outstanding financial and connections, relations and affiliations relevant to the theme or materials discussed in the manuscript.

( ) The author(s)confirm that the fundings, other financial help and human/material support for this research and/or work are clearly identified in the manuscript submitted to the Editorial Board of “*Revista Brasileira de Cancerologia*”.

# Acknowledgments:

( ) The author(s) confirm that the persons who contributed substantially for the work developed in the text but that do not meet the authorship criteria were referenced in “acknowledgments” of the manuscript with the description of their contributions.

( ) The author(s) confirm that the persons listed in this section granted their written permission to be included.

( ) The author(s) confirm that if this section was not included in the text submitted is because no additional substantial contribution was made.

# Transference of copyrights/publication:

I declare that, in the event of acceptance of the manuscript for publication, I agree to assign the right of first publication to the Revista Brasileira de Cancerologia, which adopts the Creative Commons CC-BY 4.0 License and the open access policy, so the texts are available for anyone to read, download, copy, print, share, reuse and distribute, with due citation of the source and authorship.

The *Revista Brasileira de Cancerologia* considers author who meets three conditions presented in the item 1. Contributions. Who meets one or two conditions should not be considered author. In this case, the name should be included in acknowledgments with the type of contribution. The authors will be held accountable for every manuscript related aspect.

I authorize the access to the full content (data, computer codes and other materials) subjacent to the text of the article.

( ) Yes. ( ) They are part of the manuscript content.

 ( ) Will be available when the article is published.

 ( ) Are available since \_\_\_\_\_/\_\_\_\_/\_\_\_\_\_\_\_\_\_\_

 Repository: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

( ) Yes, by reviewers’ request.

 ( ) No. Justify: ­­­­­­­­­­­­­­­­­­­­­­­­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 Check the option for opening up your identity to reviewers.

 ( ) Maintain anonymity.

 ( ) Open your identity to reviewers.

Signature of the Corresponding Author:

Date: \_\_\_\_/\_\_\_\_/\_\_\_\_\_\_\_

E-mail: